å»è¬åå ¬è¡šãããæŽå¯
åç±³çç©åäžãã«ã¢ã³åžå Žã補åã¿ã€ãå¥ïŒãšã¹ããã²ã³ãããã²ã¹ããã³ããã¹ãã¹ããã³ãªã©ïŒãå€åœ¢å¥ïŒé å€ããã³ã«ãã»ã«ãã¯ãªãŒã ããã³ãžã§ã«ã泚å°å€ããããããã³ã€ã³ãã©ã³ããªã©ïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ãå°éã¯ãªããã¯ãããŒã ã±ã¢æœèšãªã©ïŒ... ãã£ãšèŠã
ãšãŒããããã¢ã»ã¢ã³ãäžæ±ããã³ã¢ããªã«ã®æ é€è£å©é£ååžå Žã補åã¿ã€ãå¥ïŒãã«ããã¿ãã³ãã¢ã·ã¥ã¯ã¬ã³ãããã³ãããã·å ¥ããã«ãããã©ã«ããã«ããã¿ãã³ããããã·å ¥ããã«ãããã©ã«ããã«ããã¿ãã³ããããŠçš®åãšãã¹å ¥ããã«ãããã©ã«ããã«ããã¿ãã³ãã€ãã§ãŠèãšãã¹å ¥ããã«ãããã©ã«ããããŠçš®åãšãã¹ããªã¿ããã³ãžã³ïŒã³ãªã³ããã«ããã¿ãã³ãã¢ãªã³ã¬å ¥ããã«ãããã©ã«ãããã³ ãã®ä»ïŒãçšéå¥ïŒæ§ã®å¥åº·ãå°å ã®å¥åº·ã女æ§ã®å¥åº·/婊人ç§ïŒã補å€å¥ïŒã«ãã»ã«ãé å€ãç²æ«ïŒãæµéãã£ãã«å¥ïŒåžå£²æ¥è ãšé»ååååŒïŒ... ãã£ãšèŠã
HIV-associated lipodystrophyå¥ålipodystrophyã¯HIVææããæ£è ã§èµ·ããã·ã³ãããŒã ã§ãã ããã¯é¡ããã¿ããã¯ãè ããã³è¶³ããã®ç®äžèèªã®æå€±ã«ãã£ãŠç¹åŸŽä»ããããŸãã HIV-associated lipodystrophy ã®æ£ç¢ºãªåå ã¯ååã«å®¹èªãããŠããŸããããæã¬ãããŠã€ã«ã¹è¬äžã«ããHIVæææ£è ã§èµ·ããããã€ãã®ç ç©¶ã®èšŒæ ã 2014幎ã«åœç«ç ç©¶éçºæ³äººãã€ãªãã¯ãããžãŒæ å ±ã»ã³ã¿ãŒ(NCBI)ã«æ²èŒãããèšäºã«ãããšãHIVã«ææãã人ã ã®lipodystrophyã®èå»¶ã¯10%ãš80%ã®éã§å€åããŸããHIVã®æ®åçã¯ãHIV-as... ãã£ãšèŠã
骚ã®ã»ã¡ã³ãã¯éªšãžã®æ¥åç®æã®æ³šå ¥ã®åºå®ã®ããã«äœ¿çšãããææã§ãã ããªã¡ãã«ã¡ã¿ã¯ãªã¬ãŒã(PMMA)ãŸãã¯å ±éåäœãæ§æããããªããŒããŒã¹ã®ææã§ããååŠéªšã®ã»ã¡ã³ãã¯Plexiglasã§ãã æŽåœ¢å€ç§äžã®ææã¯ãæçç©è³ªã®éªšã®ã»ã¡ã³ãã®äœ¿çšãäžå¯æ¬ ã§ããäž»èŠãªæžå¿µã§ãã é³é ææã¯å£ãããããŸãã¯å·ã€ããããéªšãæ¯ããã®ã«äœ¿çšãããŠããŸãã ãããã®ææã¯ãå£ãã骚ã®åšãã«æ¯æçãªã©ãããå 垯ãšããŠæ©èœããŸãã é³é ææã¯ããŸããŸãªåœ¢ããã³ãµã€ãºã§å©çšã§ããŸãããæçç©è³ªã®éªšã®ã»ã¡ã³ãã§äœ¿çšãããé³é ææã®æãäžè¬çãªã¿ã€ãã¯ãã©ã¹ã¿ãŒããã³ã¬ã©ã¹ç¹ç¶ã§ãã ç§ãéè·¯äºæ ãã¹ããŒãå·å®³... ãã£ãšèŠã
ã¿ãŠãªã³åžå Žã補åã¿ã€ãå¥ïŒåæã¿ãŠãªã³ããã³å€©ç¶ã¿ãŠãªã³ããã³çç©ç±æ¥ã¿ãŠãªã³ïŒãã°ã¬ãŒãå¥ïŒé£åããã³é£²æã°ã¬ãŒããå»è¬åã°ã¬ãŒãã飌æã°ã¬ãŒããåç²§åã°ã¬ãŒããªã©ïŒãçšéå¥ïŒæ é€ããªã³ã¯ãæ é€è£å©é£åãåç©é£Œæããã³ãããããŒããå»è¬åãä¹³å çšãã«ã¯ãåç²§åããã³ããŒãœãã«ã±ã¢ãªã©ïŒãæµéãã£ãã«å¥ïŒB2BçŽæ¥è²©å£²ãæå販売æ¥è ããªã³ã©ã€ã³B2Bãã©ãããã©ãŒã ãããã³ ãã®ä»)ãå°çå¥ (åç±³ãã©ãã³ã¢ã¡ãªã«ããšãŒããããã¢ãžã¢å€ªå¹³æŽãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
ãªãã«ã€ã³ãããã¯çµç®åžåå補å€ã§ãç é¢ãå°å£²åºããªã³ã©ã€ã³è¬å±ã§è³Œå ¥ã§ãããçã¿æ¢ããšããŠæãäžè¬çã«åŠæ¹ãããããŸããç¥çµçŸæ£ã«é¢é£ããçã¿ã®æ²»çãé·æçãªçã¿ã®åé¡ã®ç·©åã垯ç¶ç±ç¹ã«ããçã¿ã®ç·©åã«ã䜿çšãããã äžçã®ãªãã«ã€ã³ãããåžå Žã¯ã2022幎ã«ã¯10å5,560 äž ç±³ãã«ãš æšå®ãããäºæž¬æéïŒ2022-2030幎ïŒã«ã¯ CAGR 7.8 %ã瀺ããšäºæ³ãããŠããã å³1.ãªãã«ã€ã³ãããã®äžçåžå Žãéé¡ããŒã¹ïŒçŸäžç±³ãã«ïŒãå°åå¥ã2022幎 ãžã§ããªãã¯ãªãã«ã€ã³ããã補åã®å°å ¥ããäºæž¬æéäžã®äžçãªãã«ã€ã³ãããåžå Žã®æé·ãä¿é²ãããšäºæ³ãããã ãªãã«... ãã£ãšèŠã
Trigeminalç¥çµç(TN)ãå¥åtic douloureuxã¯ã第5é è³ãŸãã¯äžè§ç¥çµã«åœ±é¿ãäžããæ ¢æ§çŒçé害ã§ãã ã©ã€ã ç ããµã«ã³ã€ããŒã·ã¹ãå€çºæ§ç¡¬åçãå«ãå šèº«çŸæ£ã«ããççç¶æ ãåŒãèµ·ãããŸãã ãŸããå šèº«ã®Lupus erythematosusããã³sclerodermaãå«ãã³ã©ãŒã²ã³ã®è¡ç®¡çŸæ£ãšã®é¢é£ä»ãããããŸãã ç¥çµå€ç§ä»å ¥ãèŠæ±ããããŸã§ãé€ããŠãæ¡ä»¶ã¯å€æ¥åºç€ã§åŠçãããŸãã ãã®ç®¡çã¯ãæ£è ã®äžè¬çãªç¶æ ãšå¹Žéœ¢ã«åºã¥ããŠãåå¥ã«ã«ã¹ã¿ãã€ãºããå¿ èŠããããŸãã ããããæ¡ä»¶ã®æ£ç¢ºãªåå ã¯äžæã§ããTrigeminalç¥çµçã®åŠçœ®ã®åžå Žã¯è¬ç©çæ³ããã³å€ç§ã«... ãã£ãšèŠã
çµå£ã¯ãæäžã®çµå£çµè·¯ä»¥å€ã®ã«ãŒããä»ããŠç®¡çãããçæ®äžèœã®æäžéã®åœ¢æ ã§ãã 圌ãã¯çŽæ¥ãã£ãã·ã¥ãè¡ç®¡ãšæ¥è§ŠããŠç®ããã³æå¹æåã®1ã€ä»¥äžã®å±€ã«æ³šå ¥ãããŸãã 倧ãã容ç©ã®parenteralã¯2ã€ã®ã¿ã€ãã§ããå°ãã容ç©ã®parenteralã¯å®¹ç©100 mlãããå°ãªãéã®åäžãå€éã®æºåã§ãã倧ãã容ç©ã®parenteralã«100 ml以äžã®å®¹ç©ããããŸãã 倧容éã®æ¬åŒ§ã¯ãéèå æäžã®ããã®è¢ãŸãã¯ããã«ã«å ¥ã£ãŠãããæ¶²äœ/é»è§£æ¶²ãã©ã³ã¹ã®è£æ£ã«äœ¿çšãããããã¹ãããŒã¹ãªã©ã®æ é€ãæäŸããŸããç·©åã±ã¢ã®å¿ èŠæ§ãå¢å ãã倧容é éçµå£åžå Žã®æé·ãä¿é²ããããã®ããå€ç§çåŠçœ®ã®å¿ èŠ... ãã£ãšèŠã
ç±³åœããã³ãšãŒãããã®èšåºæ é€åžå Žãæäžçµè·¯å¥ïŒçµå£ãçµè žãéçµå£ïŒãçšéå¥ïŒãããä»£è¬æ§çŸæ£ãèè žçŸæ£ãç¥çµçŸæ£ãªã©ïŒã幎霢局å¥ïŒæäººãå°å ãé«éœ¢è ïŒãæµéãã£ãã«å¥ïŒç é¢è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±ïŒ... ãã£ãšèŠã
Liposarcoma ã¯æããã蚺æãããã¿ã€ãã®è»çµç¹ã® sarcomas ã® 1 ã€ãæããŸãã èèªçްèããæ·±ãçµç¹ã«ç±æ¥ããããã®äžçš®ã§ãã äžæ¹ãéå岿§ãªããµã«ãã¯ããµã«ã³ãã®ãã¹ãŠã®çš®é¡ãšåååè£ãããµã«ãããçããæãäžè¬çãªãµãã¿ã€ãã§ãã çµé²ããããªããµã«ãã®è «çã¯ãå žåçã«ã¯ã暪ããã£ãåŸæ¹/è ¹è ã«ååšããã ãããã®è «çã®çºçã®çç±ã¯ãŸã äžæã§ãããéºäŒåå€ç°ã¯ããããã®è «çã®çºçå åã®1ã€ã§ãããšèããããŠããŸãã é€èããã³æšçå ç«çæ³ã®ãããªããŸããŸãªçæ³ã«ãã£ãŠè «çã®å®å šãªåé€ããã³åãå€ããå«ãdedifferentiated sarcomaã®ããã®æãäž... ãã£ãšèŠã
Measlesãmumpsãããã³ rubellaã¯ãææãã人ã®çã¿ãå³ã«ãã£ãŠéä¿¡ããããŠã€ã«ã¹ã«ãã£ãŠéåžžã«åŒãèµ·ãããã3ã€ã®äžè¬çãªäŒææ§ç©ºæ°åªä»çŸæ£ã§ãããåäŸã®éã§æ·±å»ãªå䜵çãæ»ã«ã€ãªããå¯èœæ§ããããŸãã ãããã®ç æ°ã®ã¯ã¯ãã³ã¯ãåçµããããŠã€ã«ã¹ã¯ã¯ãã³ãšããŠè²©å£²ãããŠããŸãã, åçµä¹Ÿç¥è£œå€ã§è£œé , 泚å°çšåžéã®ããã®æ°Žãšåæ§æãå¿ èŠãšãããš2ã€ã®åœ¢æ ã§å©çšå¯èœã§ã. äŸãã°å䟡ã ãã§ãªããçµã¿åããã¯ã¯ãã³. MMRã¯ã¯ãã³ã¯ã2ã€ä»¥äžã®ãŠã€ã«ã¹æ ªã®æ··åç©ã§æ§æãããŠããŸãã ãããã®ã¡ã¢ã¹ã¬ããã ãŒãããã³ã«ãã©ã¯ã¯ãã³ã¯ãå°å ã ãã§ãªã倧人ã«ãç®äžæ³šå°ã«ãã£ãŠæäž... ãã£ãšèŠã
Osteonecrosisã¯éªšçްèã骚ã«è¡ã®æµãã®æ¬ åŠã«ãã骚现èã®ãã€ã¹ã骚ã厩å£ããç æ°ã§ãã è¡ç®¡ç¥çµçãç¡èç¥çµçãŸãã¯èè¡æ§ç¥çµçãšããŠãç¥ãããŠããŸãã Osteonecrosisã¯è©ãæéŠãæè¶³ããã³ãã£ãŒãã§ããå°ãªãé »ç¹ã«éããããã®éªš(femur)ãèã§æãäžè¬ã«çºéããŸãã 軜床ããé床ã®çã¿ãåŒãèµ·ããã埮å°éªšæã«ã€ãªããå¯èœæ§ããããŸãã Osteonecrosisã¯Xç·ãCTã¹ãã£ã³ãMRIã骚ã¹ãã£ã³ããã³æ©èœéªšãã¹ãã䜿çšããŠèšºæããããšãã§ããŸãã Osteonecrosisã®åŠçœ®ã¯åŸŽåãç®æšã«ããæ¥µç«¯ãªå Žåã®è¬ç©ãå€ç§ã«ãã£ãŠèŠçãæžãããŸãã åžå°çŸæ£ã®åœ... ãã£ãšèŠã
æ¿ãã䟵襲çã¢ã¹ãã«ã®ã«çã¯ãã¢ã¹ãã«ãžã«èã«ããæ¥æ§ææçãŸãã¯çèæé·ã§ãã ã»ãšãã©ã®äººã¯ã¢ã¹ãã«ãžã«ã¹èãšæ¥è§ŠããŠããŸããã誰ããææã«ææã§ã¯ãããŸããã ã¢ã¹ãã«ã®ã«çã¯ã䟵襲çã¢ã¹ãã«ã®ã«çãæ ¢æ§èºã¢ã¹ãã«ã®ã«çãã¢ã¬ã«ã®ãŒæ§æ°ç®¡è «çãã¢ã¬ã«ã®ãŒæ§ã¢ã¹ãã«ã®ã«çãã¢ã¬ã«ã®ãŒæ§ã¢ã¹ãã«ã®ã«çãã¢ã¹ããŒãžã«çãããã³ç²èçãªã©ã®ããŸããŸãªã¿ã€ãã«åé¡ãããŸãã æŽ»åçãªäŸµè¥²çãªã¢ã¹ãã«ã®ã«ç(IA)ã¯ãå ç«æåã®æ£è ãèºçŸæ£ã«èŠããã§ãã人ã«åœ±é¿ãäžãããŸãã§ãäžåè¡¡ãããã³æ·±å»ãªçèææçã§ãã 䟵襲çãªã¢ã¹ããŒãžçã®äŒæã®éçºã«è²¬ä»»ãããå±éºå åã¯åŒ±ããããå ç«ã·ã¹ãã ãäœãçœè¡... ãã£ãšèŠã
ã¢ãžã¢å€ªå¹³æŽã€ãã°ã«ã»ã©ãŒãŒåžå Žã匷床å¥ïŒ400 IUããã³200 IUïŒããã©ã³ãå¥ïŒã»ã¬ã¶ã€ã ãã¢ããµãŒãã³ããã®ä»ïŒãå°åå¥ïŒäžåœãã€ã³ããã·ã³ã¬ããŒã«ãã¿ã€ããããã ããã¬ãŒã·ã¢ããã£ãªãã³ãã€ã³ããã·ã¢ãã«ã³ããžã¢ãããã³ãã®ä»ã®ã¢ãžã¢å€ªå¹³æŽå°åïŒ... ãã£ãšèŠã
Thrombocytopeniaã¯æ£è ãè¡äžã®è¡å°æ¿ã®äœã¬ãã«ãæã£ãŠããé害ã§ãã è¡å°æ¿æžå°çã®äž»ãªåå ã¯ãè¡å°æ¿ãè¡å°æ¿ã®èŸèã®åé¢ãããã³è¡å°æ¿ã®å éç Žå£ã®éå¹ççãªçç£ã§ãã è¡æ çã®æãäžè¬çãªéæå¹ãªçç£ã¯ãéªšé«æ§çå矀ããã©ã¹ããã¯è²§è¡ãªã©ã®éªšé«ã®æ éçå矀ã§ãã Thrombocytopeniaã¯ç¶æ¿ãŸãã¯ååŸããããšãã§ããŸãã ã§ 2014, å°éå®¶ã®Med Jã§å ¬è¡šã®ç ç©¶èšäºã«ãããšã, 2014, ããã³ãã·ãŒãopeniaã®åšæ³¢æ°, thrombocytopeniaã®åšæ³¢æ°ã¯ãé«éœ¢è ã®ããã®ããé«ãã§ã 60 æ³ä»¥äž, éè¡çªèçŸæ£ã«èŠãã. ããããªãããã¿ã³ãã... ãã£ãšèŠã
è³åäžã¯è¡æ¶²ååºãè¡ç®¡ããããã¯ããè¡æ¶²ã®æµããè³ã«é®æããçŽ°èæ»ã«è³ãç¶æ ã§ãã ã¢ã¡ãªã«ã³ã¹ãããŒã¯åäŒã®ã¬ã€ãã©ã€ã³ã§ã¯ã3çš®é¡ã®ã¹ãããŒã¯ããããŸã:èè¡æ§è³åäž(è³ã«è¡æ¶²ãå±ããè¡ç®¡å ã®éå¡)ãåºè¡æ§è³åäž(é«è¡å§ã«ããè¡ç®¡ã®æŽå)ãããã³éæž¡æ§èè¡æ§çºäœ(äžæçãªè æã«ãã£ãŠèå¥ããã)ã é«è¡å§ãç³å°¿ç ãå¿èç ããŸãã¯å«ç ã身äœçã«äžæŽ»æ§ãªã©ã€ãã¹ã¿ã€ã«ãã¢ã«ã³ãŒã«ä¹±çšãè¥æºãªã©ã®ããŸããŸãªç¿æ £ãªã©ã®å»åŠçæ¡ä»¶ã«èµ·å ããã¹ãããŒã¯ã¯åŒãèµ·ããããšãã§ããŸãã ãŸããé«éœ¢åãç·æ§ã®æ§ãéºäŒæ§ãæ°ææ§ãªã©ã®å¶åŸ¡äžèœãªèŠå ãè³åã«è²¢ç®ããŸãã 2015幎ã«äžçä¿å¥æ©é¢(WHO)ã«ãããš... ãã£ãšèŠã
æ¥æ§ãªã³ãèœçæ§çœè¡ç(ALL)ã¯ã骚é«ãè¡æ¶²ã«åœ±é¿ãäžããçã®äžçš®ã§ãã æ¡ä»¶ã¯ããªã³ãèœçްèãšãåŒã°ããèªç¶çœè¡çã®éå°çç£ã«ãã£ãŠç¹åŸŽä»ããããŸãã äžåäžãŸãã¯ç°åžžãªçްèã¯ãé©åã«æ©èœããå¥åº·ãªçްèã®åšãã«æ§ç¯ããããšã¯ã§ããŸããã ãã¹ãŠã®æ£è ã¯ãåçºææãè²§è¡ãåºè¡ãããã³éªšé«ãèµ€è¡çãçœè¡çããã³è¡å°æ¿ã®ååãªæ°ã圢æã§ããªãããã容æã«å·ã€ãããšã¯éåžžã«ææã§ãã ããã¯é«ãé²è¡çãç¹åŸŽãšããæ°ãæä»¥å ã«æ²»çããªããšèŽåœçã§ããã ãã现èã¯ããªã³ãç¯ãèèãèŸèãäžæ¢ç¥çµç³»ãå«ãäœã®ä»ã®èåšã«åºããå¯èœæ§ãããã ç¶æ ã®äžè¬çãªçç¶ã«ã¯ãè äžå šãèºçãåŒåžåšçŸæ£ãããã³éªšã®ç... ãã£ãšèŠã
äºæ¬¡ç²ç¶è ºæ©èœäº¢é²ç(SHPT)ã¯ãäž»ã«ç²ç¶è ºãã«ã¢ã³ãããã©ã«ä»£è¬ç°åžžãããã³å¯ç²ç¶è ºæ©èœäº¢é²çã®é«ã¬ãã«ã«ãã£ãŠç¹åŸŽä»ããããæ ¢æ§è çŸæ£(CKD)ãšé¢é£ããæ·±å»ãªãå ±éããã³é²è¡å䜵çã®1ã€ãæããŸãã ç æ°ã®è èã¯ããã¿ãã³Aããã®æŽ»æ§åœ¢æ ã«å€ããããšãã§ããªããããäœå ã§äžæº¶æ§ã«ã«ã·ãŠã ãªã³é žå¡©ã®åœ¢æã«é©ããªããããäºæ¬¡ç²ç¶è ºæ©èœäº¢é²ã«ã€ãªããã ç æ°ã®äžè¬çãªåŸŽåããã³åŸŽåã¯éªšããã³æ¥åç®æã®èŠçããŸãè¢ã®å€åœ¢ãå«ãã§ããŸãã äºæ¬¡ç²ç¶è ºæ©èœäº¢é²çã®æ£è ã«åŒãèµ·ããããé害ã¯ãçåœãšçåœã®æåŸ ã®æªãå質ã«ã€ãªããå¯èœæ§ããããŸãã SHPTã®ããã®åŠçœ®ã¯å諟ãããã¿ãŒã²ããåºåå ã®å¯... ãã£ãšèŠã